Cd7-car-t cell,and preperation method therefor and use thereof

GB2629941APending Publication Date: 2024-11-13ADVANCED BIOTHERAPEUTICS LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
GB2024010379
Authority / Receiving Office
GB · GB
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-28
Filing Date
2023-01-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Existing CD7-CAR-T cells face the risk of "cannibalism" and side effects when treating T-cell acute lymphoblastic leukemia and CD7-positive lymphoma, and are difficult to effectively prepare and safely apply.

Method used

By designing a unique anti-human CD7 monoclonal antibody sequence and integrating it with the endoplasmic reticulum localization signal to block the expression of CD7 antigen on the surface of CAR-T cells, combined with the suicide gene structure to ensure safety, CD7 blocking molecules and embedded Combine antigen receptors to avoid "cannibalism" and control the survival of CAR-T cells.

Benefits of technology

It achieves the effective preparation and in vitro production of CD7-CAR-T cells, avoids the "cannibalism" effect, ensures the safety and specific killing ability of cell therapy, and has a significant killing effect on CD7-positive target cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a CD7-CAR-T cell, and a preparation method therefor and the use thereof, wherein the CD7-CAR-T cell contains an antibody targeting a CD7 antigen or an antigen-binding fragment thereof, and the antibody or antigen-binding fragment thereof contains heavy chain variable regions of complementarity-determining regions CDR1, CDR2 and CDR3 having amino acid sequences as shown in SEQ ID NOs: 12-14, and light chain variable regions of complementarity-determining regions CDR1, CDR2 and CDR3 having amino acid sequences as shown in SEQ ID NOs: 15-17. The antibody of the present invention and CD7-CAR based on the antibody fragment have extremely strong affinity to a CD7 antigen molecule. Moreover, a blocking molecule of the present invention can almost completely block the expression of the CD7 molecule on a cell surface without substantially affecting the normal expansion of T cells, thereby effectively avoiding the self-killing between CD7-CAR-T cells. In addition, the CD7-CAR-T cells of the present invention have a significant and specific killing effect on CD7-positive target cells, and provide beneficial CAR-T cells for the clinical application of cell therapy.
Need to check novelty before this filing date? Find Prior Art

Description

CD7-CAR-T cells and preparation methods and applications thereof Technical Field

[0001] The present invention relates to the field of biological immunotherapy technology, and specifically to CD7-CAR-T cells and their preparation methods and applications. Background Art

[0002] Acute lymphocytic leukemia (ALL) is a common hematologic malignancy, primarily originating from B and T lymphocytes. Primitive, immature lymphocytes undergo multiple steps of specific genetic damage to form tumor cells. These cells then abnormally proliferate and aggregate in the bone marrow, suppressing the hematopoietic function of normal bone marrow stem cells and leading to the development of ALL. Furthermore, these tumor cells can infiltrate tissues outside the bone marrow (such as lymph nodes, meninges, liver, and gonads), causing related tissue damage.

[0003] ALL can occur in all age groups, with a higher incidence of 3.6 per 100,000 children and young adults, and a lower incidence of 0.69 per 100,000 adults. Initial chemotherapy and targeted therapies can kill aggressive proliferating cells and cells with selective or acquired mutations, but drug-resistant ALL cells can still lead to relapse. Bone marrow transplantation is an important treatment for ALL. Although allogeneic transplantation is highly effective for acute leukemia, it is significantly limited by the lack of suitable donors and the high cost of transplantation for most patients. Autologous bone marrow transplantation, as an alternative to allogeneic transplantation, has rapidly developed in recent years. Although a considerable amount of clinical data has been accumulated, the role of autologous bone marrow transplantation in the treatment of acute leukemia remains controversial due to the wide disparity in efficacy reported. The long-term leukemia-free survival (LFS) rate of autologous bone marrow transplantation in the initial complete remission period ranges from less than 30% to over 70%. Some data suggest that autologous bone marrow transplantation does not improve LFS in patients with acute lymphoblastic leukemia. However, other data demonstrate that the efficacy of autologous bone marrow transplantation for patients with acute lymphoblastic leukemia who have achieved initial complete remission is similar to that of allogeneic bone marrow transplantation and far superior to chemotherapy alone. Therefore, given the uncertainty and low efficacy of existing treatments, the search for new and better treatments is ongoing.

[0004] Acute T-lymphocytic leukemia (T-ALL), a type of ALL, is a malignant tumor caused by the malignant transformation and clonal expansion of T-lineage precursor cells in the bone marrow and thymus. T-ALL is characterized by diverse and highly heterogeneous genetic mutations, including gene deletions, mutations, and chromosomal translocations. These abnormalities can lead to abnormalities in various signaling pathways (such as MAPK and Jak / Stat, PI3K / Akt / mTOR, etc.) and / or the cell cycle. Studies have identified at least 170 potential oncogenic driver genes associated with the development of T-ALL.

[0005] T-ALL mostly occurs in children and adolescents, but can also occur in adults. T-ALL accounts for 10%-15% of pediatric ALL patients and approximately 25% of adult patients. Compared to B-cell acute lymphoblastic leukemia (B-ALL), T-ALL is insensitive to chemotherapy, has poor therapeutic effects, a high relapse rate, and low remission and long-term survival rates. The dominant clones after relapse are often rich in genes that are resistant to conventional chemotherapy drugs. Compared to pediatric T-ALL, adult T-ALL has a worse treatment effect. Approximately 50% of adult patients relapse about a year after remission from treatment, and the remission rate with re-chemotherapy is only 30%-45%. Ultimately, only 40% of patients achieve long-term survival, and the prognosis for patients with relapsed / refractory T-ALL is generally even worse.

[0006] In recent years, chimeric antigen receptor T cell (CAR-T) therapy has demonstrated remarkable clinical efficacy in the treatment of hematologic malignancies, bringing new hope to cancer treatment. For example, CAR-T therapy targeting CD19 can achieve 90%-100% remission rates in B-ALL, and both autologous and allogeneic CAR-T therapy can achieve relapse-free survival of more than five years. One of the key techniques in CAR-T therapy is to select a specific target expressed on tumor cells, such as a tumor-associated antigen or tumor-specific antigen, and then use specific antibodies against this antigen to prepare CAR-T cells for treatment.

[0007] CD7 is a 40kDa single-chain cell membrane glycoprotein primarily expressed on thymocytes and most peripheral blood T lymphocytes. It precedes the appearance of other T-cell antigens (CD1, CD2, CD3, CD4, CD5, and CD8) and the rearrangement of the TCR-β chain gene. The CD7 antigen is also expressed on NK cells and some myeloid cells. It is highly expressed on the surface of leukemic cells originating from the T lymphoid lineage. In addition to T-ALL, the vast majority of T-cell lymphomas, NK, and NKT lymphomas also express CD7, and its expression rate is also 20-30% in acute myeloid leukemia (AML). However, animal experiments have shown that mouse T progenitor cells with CD7 knockout still produce normal T cell development and homeostasis, with minimal changes in T cell effector function, suggesting that CD7 does not have a critical impact on T cell development and function. Therefore, CD7 is an ideal target for T-ALL and CD7-positive tumors.

[0008] Compared to CAR-T therapy for B-ALL, the application of CD7-CAR-T cells for the targeted treatment of T-cell acute lymphoblastic leukemia and CD7-positive lymphomas still faces significant technical challenges. This is because both normal effector T cells and T-cell tumors express the CD7 antigen, which can lead to a "fratricidal" effect of CD7-CAR-T cells. Therefore, CD7-CAR-T cells are difficult to successfully generate in vitro. In clinical applications, it is also important to consider that CD7-CAR-T cells should not be allowed to persist indefinitely in vivo to avoid serious side effects. Currently, only a few CD7-CAR-T technology studies have been conducted. To avoid this "fratricidal" effect, CRISPR gene editing is used to knock out the CD7 gene in T cells. However, achieving 100% knockout of the CD7 molecule is difficult, both in practice and in theory, and the risk of graft-versus-host disease (GVHD) remains in clinical practice. Furthermore, the potential side effects of natural "off-target" effects of gene editing also limit its widespread clinical application. While the use of nano-body technology to reduce the size of the antibody binding region has certain advantages, the disadvantage is that the smaller, single-armed antibody will lead to a relative weakening of the antigen-antibody binding force and stability, resulting in reduced CD7-CAR-T cell efficacy. In addition, normal T cells, NK cells, etc. also express CD7, which is an important force in maintaining normal cellular immunity and fighting viral and bacterial infections in the body. Only emphasizing the long-term lethality of CD7-CAR-T cells in the body while eliminating tumors can cause long-term side effects such as infection. Therefore, the rational control of the presence of CD7-CAR-T cells is also an important factor in excellent CAR-T design.

[0009] The information in the background technology is only intended to illustrate the general background of the invention and should not be regarded as an admission or any form of suggestion that this information constitutes the prior art known to a person skilled in the art.

[0010] Summary of the Invention

[0011] In order to solve the technical problems in the prior art, the inventors have conducted in-depth research, prepared and selected a unique anti-human CD7 monoclonal antibody sequence as the antigen recognition element constructed by the CD7-CAR-T of the present invention, and simultaneously applied the structure of the anti-CD7 antigen antibody fragment fused with the endoplasmic reticulum (ER) localization signal to position the CD7 antigen molecule in the ER reticular cavity of the T cell to block its expression on the surface of the CAR-T cell, thereby eliminating the "cannibalism" effect of the CD7-CAR-T cell, so as to facilitate the in vitro preparation and production of CD7-CAR-T cells. In addition, the present invention applies a suicide gene structure to the CAR-T structure, which can eliminate CAR-T cells when not needed to ensure the safety of its application. Specifically, the present invention includes the following contents.

[0012] In a first aspect of the present invention, an antibody or antigen-binding fragment thereof is provided, comprising a heavy chain variable region comprising complementary antigen determining regions CDR1, CDR2 and CDR3 having the amino acid sequences shown in SEQ ID NOs.: 12-14; and

[0013] A light chain variable region having antigenic complementarity determining regions CDR1, CDR2 and CDR3 of the amino acid sequences shown in SEQ ID NOs.: 15-17.

[0014] According to the antibody or antigen-binding fragment thereof of the present invention, preferably, the antibody has any one of the amino acid sequences shown in (I), (II) or (III):

[0015] (I) the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 9 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 11;

[0016] (II) an amino acid sequence having at least 90%, preferably at least 95%, even more preferably at least 98%, and most preferably at least 99% homology to the amino acid sequence shown in SEQ ID NO.: 9 and 11;

[0017] (III) amino acid sequences obtained by modifying, substituting, deleting or adding one or more amino acids to the amino acid sequences shown in SEQ ID NOs.: 9 and 11;

[0018] The amino acid sequence has the activity of an antibody against the CD7 antigen.

[0019] According to the antibody or antigen-binding fragment thereof of the present invention, preferably, the antibody comprises at least one of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody or a bispecific antibody; and the antigen-binding fragment comprises at least one of a Fab fragment, a Fab', a F(ab')2 fragment, a single-chain variable fragment scFv, a scFv-Fc fragment or a single-chain antibody ScAb.

[0020] The second aspect of the present invention provides a CD7 blocking molecule comprising:

[0021] a. the antibody or antigen-binding fragment thereof according to the first aspect; and

[0022] b. Endoplasmic reticulum localization domain.

[0023] A third aspect of the present invention provides a chimeric antigen receptor comprising:

[0024] 1) an antigen-binding domain that recognizes the CD7 antigen, wherein the antigen-binding domain comprises the antibody or antigen-binding fragment thereof according to the first aspect;

[0025] 2) a transmembrane domain; and

[0026] 3) intracellular signaling domain;

[0027] Preferably, further comprising a hinge region;

[0028] Preferably, it further comprises a suicide switch molecule;

[0029] Preferably, further comprising an intracellular costimulatory domain;

[0030] Preferably, the transmembrane domain is selected from the group consisting of polypeptides CD28, NKp30, CDS, DAP10, 4-1BB, DAP12, CD3C, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGH TR), SLAMF7, NKp80(KLRF1), CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, I TGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, At least one of DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96, CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, or a combination thereof;

[0031] Preferably, the intracellular signaling domain is selected from the group consisting of: CD8, CD3ζ, CD3δ, CD3γ, CD3ε, FcγRI-γ, FcγRIII-γ, FcεRIβ, FcεRIγ, DAP10, DAP12, CD32, CD79a, CD79b, CD28, CD3C, CD4, b2c, CD137 (4-1BB), ICOS, CD27, CD28δ, CD80, NKp30, OX40, or any combination thereof.

[0032] In a fourth aspect, the present invention provides an isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to the first aspect of the present invention, or the blocking molecule according to the second aspect, or the chimeric antigen receptor according to the third aspect.

[0033] The fifth aspect of the present invention provides a vector comprising the nucleic acid molecule according to the fourth aspect.

[0034] The sixth aspect of the present invention provides a host cell comprising the vector according to the fifth aspect.

[0035] The seventh aspect of the present invention provides a method for preparing the chimeric antigen receptor according to the third aspect, comprising culturing the host cell according to the sixth aspect.

[0036] In an eighth aspect, the present invention provides an immune effector cell expressing the antibody or antigen-binding fragment thereof according to the first aspect of the present invention, or the blocking molecule according to the second aspect, or the chimeric antigen receptor according to the third aspect;

[0037] Preferably, the immune effector cells are selected from at least one of: leukocytes, monocytes, macrophages, dendritic cells, mast cells, neutrophils, basophils, eosinophils, αβT cells, γδT cells, natural killer (NK) cells, natural killer T (NKT) cells, B cells, innate lymphoid cells (ILCs), cytokine-induced killer (CIK) cells, cytotoxic T lymphocytes (CTLs), lymphokine-activated killer (LAK) cells, T lymphocytes, peripheral blood mononuclear cells and hematopoietic stem cells.

[0038] In a ninth aspect, the present invention provides use of an agent in preparing a composition, a medicament, a preparation, or a kit for preventing and / or treating cancer or tumors, the agent comprising: the antibody or antigen-binding fragment thereof according to the first aspect of the present invention, or the blocking molecule according to the second aspect, or the chimeric antigen receptor according to the third aspect, or the immune effector cell according to the eighth aspect;

[0039] Preferably, the cancer or tumor refers to a cancer or tumor associated with CD7 expression. Also preferably, the cancer or tumor is a hematological malignancy; further preferably, the hematological malignancy is a T cell-related tumor, and the T cell-related tumor includes leukemia, lymphoma, and myeloma.

[0040] In a tenth aspect, the present invention provides use of the antibody or antigen-binding fragment thereof according to the first aspect, or the blocking molecule according to the second aspect, or the chimeric antigen receptor according to the third aspect, or the immune effector cell according to the eighth aspect in combination with other drugs. Other drugs include, but are not limited to, diagnostic agents, prophylactic agents, and / or therapeutic agents.

[0041] The excellent technical effects of the present invention include but are not limited to: the antibodies of the present invention and the CD7-CAR based on the antibody fragment have extremely strong affinity with the CD7 antigen molecule, and the blocking molecules of the present invention can almost completely block the expression of CD7 molecules on the cell surface without basically affecting the normal proliferation of T cells, thereby effectively avoiding the cannibalization of CD7-CAR-T cells. In addition, the CD7-CAR-T cells of the present invention have a significant and specific killing effect on CD7-positive target cells, providing beneficial CAR-T cells for clinical application in cell therapy. At the same time, the present invention applies a suicide gene structure to the CAR-T structure, which can eliminate CAR-T cells when not needed to ensure the safety of its application. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 is a plasmid map of the third-generation lentiviral vector pCDH-EF1(X6)-MCS-T2A-Puro.

[0043] Figure 2 is a schematic diagram of the molecular structure of CD7-Blocker.

[0044] Figure 3 is a schematic diagram of the CD7-CAR molecular structure.

[0045] Figure 4 shows flow cytometry analysis of the blocking effect of CD7-Blocker on CD7 molecules on the surface of Jurkat cells. A to E correspond to the expression of CD7 molecules on the surface of Jurkat cells transduced with different viral MOI values, with M0, M2.5, M5, M10, and M15 representing MOIs of 0, 2.5, 5, 10, and 15, respectively.

[0046] FIG5 is a flow cytometric analysis of the blocking effect of CD7-Blocker on CD7 molecules on the surface of T cells.

[0047] Figure 6 is a flow cytometry graph showing the positive rate of CD7 molecules and CAR on the surface of T cells.

[0048] Figure 7 is the CD7-Blocker-CAR-T cell expansion curve.

[0049] Figure 8 shows the killing curves of CD7-Blocker-CAR-T cells co-cultured with positive target cells U87-CD7-eGFP. The three curves correspond to the co-cultured cell groups: target cells U87-CD7-eGFP alone (a), control CD7-Blocker-T: U87-CD7-eGFP (b), and CD7-Blocker-CAR-T: U87-CD7-eGFP (c).

[0050] Figure 9 shows the killing curves of CD7-Blocker-CAR-T cells co-cultured with negative target cells U87. The three curves correspond to the co-cultured cell groups: single control target cells U87 (b'), control CD7-Blocker-T: U87 (a'), and CD7-Blocker-CAR-T: U87 (c').

[0051] Figure 10 shows the killing efficiency of CD7-Blocker-CAR-T on CD7-positive target cells U87-CD7-eGFP. DETAILED DESCRIPTION

[0052] Now, various exemplary embodiments of the present invention are described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, characteristics, and embodiments of the present invention. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area (e.g., with reference to "Molecular Cloning Experiment Guide" by J. Sambrook et al., translated by Huang Peitang et al., 3rd edition, Science Press) or the product instructions are used. Reagents or instruments used without indicating the manufacturer are conventional products that can be obtained commercially.

[0053] It should be understood that the terms described in the present invention are only for describing particular embodiments and are not intended to limit the present invention. In addition, for the numerical ranges in the present invention, it should be understood that the upper and lower limits of the ranges and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value within any stated value or stated range and any other stated value or intermediate value within the stated range is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0054] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0055] The heavy and light chain variable regions of an antibody typically include three complementary determining regions (CDRs) and four framework regions (FRs). The CDRs are connected by the framework regions. During antibody recognition, the FR molecules curl to bring the CDR molecules closer together. The CDRs are the binding sites between the antibody or antigen-binding fragment and the antigen. Therefore, the sequence of the CDRs determines the specificity of the antibody. As understood in the art, an antibody is a glycoprotein or antigen-binding portion thereof comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. The heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). The light chain comprises a light chain variable region (VL) and a light chain constant region (CL). The variable regions of the heavy and light chains comprise framework regions (FRs) and complementary determining regions (CDRs). The four FRs are relatively conserved, while the CDR regions (CDR1, CDR2, and CDR3) comprise hypervariable regions.

[0056] As used herein, an "antigen-binding fragment" refers to a polypeptide fragment that comprises a portion of an intact antibody, such as the antigen-binding region or variable region of an intact antibody, and has the property of specifically targeting CD7. Preferably, it comprises at least one CDR of the heavy chain variable region and / or light chain variable region of an antibody; further preferably, it may comprise CDR1-3 of the heavy chain variable region and / or CDR1-3 of the light chain variable region. Antigen-binding fragments can be prepared by a variety of techniques, including but not limited to proteolytic digestion of intact antibodies, or expression in host cells containing the antigen-binding fragment.

[0057] The present invention provides the above-mentioned CD7-targeting antibody or antigen-binding fragment thereof, which has good safety and targeting properties, can specifically bind to the extracellular domain of human CD7, and a vector containing the coding sequence of the antibody or antigen-binding fragment thereof is used to infect immune cells, thereby obtaining immune effector cells that have a significant killing ability against CD7-expressing tumor cells. The immune effector cells can be used to treat or improve diseases related to CD7 expression, thereby laying the foundation for the treatment of CD7-positive tumors.

[0058] Without limitation or theoretical constraints, the sequences of the heavy chain variable region CDR1, CDR2, CDR3 and the light chain variable region CDR1, CDR2 and CDR3 of the antibody or antigen-binding fragment thereof can be randomly selected within the following range: heavy chain variable regions having the antigen complementary determining regions CDR1, CDR2 and CDR3 of the amino acid sequences shown in SEQ ID NO.: 12-14; and light chain variable regions having the antigen complementary determining regions CDR1, CDR2 and CDR3 of the amino acid sequences shown in SEQ ID NO.: 15-17.

[0059] In the present invention, the antibody or antigen-binding fragment thereof has any one of the amino acid sequences set forth in (I), (II) or (III): (I) the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 9 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 11; (II) an amino acid sequence having at least 90%, preferably at least 95%, even more preferably at least 98%, and most preferably at least 99% homology to the amino acid sequences set forth in SEQ ID NOs.: 9 and 11; (III) an amino acid sequence obtained by modification, substitution, deletion, or addition of one or more amino acids to the amino acid sequences set forth in SEQ ID NOs.: 9 and 11. It should be noted that the above-mentioned homology (sometimes also referred to herein as "identity") sequences does not alter the antigen-antibody binding properties, i.e., the amino acid sequence selected from the above still retains the activity of the antibody against the tumor surface antigen CD7.

[0060] Preferably, the coding sequence of the heavy chain variable region is shown as SEQ ID NO: 22, and the coding sequence of the light chain variable region is shown as SEQ ID NO: 23.

[0061] Preferably, the amino acid sequence described herein is a sequence obtained by expressing a murine antibody coding sequence modified to account for host codon preference. In the present invention, modification to account for host codon preference refers to the substitution of bases in the base sequence according to degenerate codons to accommodate expression in different hosts. Codon modification generally does not alter the sequence of the resulting protein or polypeptide. The coding sequence for the murine antibody heavy chain variable region is shown in SEQ ID NO: 8, and the coding sequence for the light chain variable region is shown in SEQ ID NO: 10.

[0062] Preferably, the antibody comprises at least one of a monoclonal antibody, a humanized antibody, a chimeric antibody, and a bispecific antibody; and the antigen-binding fragment is at least one of a Fab, a F(ab'), a F(ab')2, a Fd, a single-chain antibody scFv, a disulfide-linked Fv (sdFv), or a single-domain antibody. Furthermore, preferably, the antibody or antigen-binding fragment thereof is humanized.

[0063] Preferably, the antibody further comprises an antibody constant region; further preferably, the antibody constant region is selected from the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD.

[0064] Preferably, the heavy chain constant region of the antibody constant region is selected from the heavy chain constant region of any one of IgG1, IgG2, IgG3, and IgG4, preferably the heavy chain constant region of IgG4; and the light chain constant region of the antibody constant region is κ or λ.

[0065] The antibodies of the present invention may comprise an Fc region derived from IgG, such as IgG1, IgG2, IgG3 or IgG4.

[0066] The term "monoclonal antibody," sometimes also referred to as "single antibody" or mAb, as used herein refers to an immunoglobulin obtained from a pure cell line, having identical structural and chemical properties and specificity for a single antigenic determinant. Monoclonal antibodies differ from conventional polyclonal antibody preparations (which typically comprise different antibodies directed against different determinants) in that each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies have the advantage that they are obtained through hybridoma or recombinant cell culture and are not contaminated with other immunoglobulins. The modifier "monoclonal" indicates the characteristic of the antibody, being obtained from a homogeneous population of antibodies, but this should not be construed as requiring any special or particular method for producing the antibody.

[0067] Variant antibodies are also included within the scope of the present invention. The present invention does not particularly limit the sequence of the variant, as long as it has binding properties targeting the CD7 antigen, or an antibody with improved affinity. Other variants with such sequences can be obtained using methods known in the art and are all included within the scope of the present invention. Those skilled in the art can modify the amino acid sequence of the polypeptide using recombinant methods and / or synthetic chemistry techniques for producing variant polypeptides. For example, amino acid substitutions can be used to obtain antibodies with further improved affinity. Alternatively, codon optimization of nucleotide sequences can be used to improve translation efficiency in expression systems for producing antibodies. Such variant antibody sequences have 80% or higher (i.e., 85%, 90%, 95%, 96%, 97%, 98%, 99% or greater) sequence identity with the sequences listed in the present invention. The sequence identity is calculated relative to the sequences listed in the present invention. Or when performing optimal alignment, such as by the program GAP or BESTFIT using the default gap weight.

[0068] As used herein, the term "modification" means that the amino acid modification does not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such modifications include amino acid substitutions, additions, and deletions. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. The antibodies of the present invention may include glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or non-naturally occurring amino acid modifications.

[0069] Conservative amino acid substitutions refer to the interchangeability of residues with similar side chains. For example, the group of amino acids with aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; the group of amino acids with aliphatic-hydroxy side chains is serine and threonine; the group of amino acids with amide-containing side chains is asparagine and glutamine; the group of amino acids with aromatic side chains is phenylalanine, tyrosine, and tryptophan; the group of amino acids with basic side chains is lysine, arginine, and histidine; and the group of amino acids with sulfur-containing side chains is cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Therefore, one or more amino acid residues in the CDR region of the antibody of the present invention can be replaced with other amino acid residues from the same side chain family.

[0070] Another possible variable region modification is to mutate the amino acid residues in the CDR1, CDR2 and / or CDR3 regions of the VH and / or VL to improve one or more binding properties (e.g., affinity) of the antibody of interest. Mutations can be introduced by site-directed mutagenesis or PCR-mediated mutagenesis. Conservative modifications (as described above) are preferably introduced. The mutations can be amino acid substitutions, additions, or deletions, but are preferably substitutions. In addition, the residue changes in the CDR regions typically do not exceed one, two, three, four, or five.

[0071] The present invention provides a CD7 blocking molecule comprising the antibody or antigen-binding fragment thereof according to the present invention and an endoplasmic reticulum localization domain. Preferably, the molecule has the amino acid sequence set forth in SEQ ID NO.:18, and its coding sequence is set forth in SEQ ID NO.:19. Furthermore, preferably, the endoplasmic reticulum localization domain has the amino acid sequence set forth in SEQ ID NO.:32, and its coding sequence is set forth in SEQ ID NO.:31. The endoplasmic reticulum localization domain contains an ER localization signal molecule, and the ER localization signal molecule has the amino acid sequence set forth in SEQ ID NO.:28, and its coding sequence is set forth in SEQ ID NO.:27.

[0072] The blocking molecules of the present invention can localize the antibody fragments of the present invention to the ER reticulum. The CD7 antigen molecules are intercepted by the antibody fragments in the ER reticulum during the secretory pathway and thus cannot be normally localized to the cell surface, thereby avoiding "internecine killing" among CD7-CAR-T cells. In another embodiment, the linker connecting the antibody fragment of the present invention to the ER localization signal molecule is a myc sequence having the amino acid sequence shown in SEQ ID NO: 33.

[0073] The present invention also provides an anti-human CD7 chimeric antigen receptor CAR, which comprises an antigen binding domain that can recognize the CD7 antigen (sometimes also referred to as an "antigen recognition region" herein), a hinge region, a transmembrane domain (sometimes also referred to as a "transmembrane region" herein) and an intracellular signaling domain (sometimes also referred to as an "intracellular region" herein), wherein the antigen recognition region comprises the antibody or antigen-binding fragment thereof that specifically binds to CD7 as described in the present invention.

[0074] In the absence of limitations, the "antigen recognition region" can be monovalent or multivalent (such as bivalent or trivalent). The antigen binding region can be monospecific or multispecific (such as bispecific). Bispecificity can be directed against CD7 and another antigen, or it can be directed against two different epitopes of CD7. Preferably, the antigen recognition region is a single-chain antibody (monovalent or multivalent). The single-chain antibody scFv includes a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region are connected by a linker (connector) to form an antibody.

[0075] Preferably, the scFv heavy chain and light chain are connected in a VH-Linker-VL or VL-Linker-VH manner. In some embodiments, the linker sequence can be selected from existing linker sequences. Also preferably, the linker sequence is (GGGGS)n, where n = 1-6. Further preferably, the linker sequence is GGGGSGGGGSGGGGS.

[0076] Preferably, the CAR further comprises a leader signal peptide sequence. In general, a signal peptide is a peptide sequence that targets a polypeptide to a desired site in a cell. In some embodiments, the signal peptide targets the polypeptide to the secretory pathway of the cell and will allow the polypeptide to be integrated and anchored to the lipid bilayer. In some embodiments, the signal peptide is a membrane localization signal peptide. Preferably, the leader peptide sequence is derived from the leader peptide sequence of CD8; more preferably, the CD8 leader peptide sequence has the amino acid sequence shown in SEQ ID NO: 36.

[0077] The "hinge region", "transmembrane region" and "intracellular region" herein can all be selected from the sequences of the hinge region, transmembrane region and intracellular region in the existing known CAR-T technology.

[0078] The hinge region of the chimeric antigen receptor is located between the extracellular antigen binding region and the transmembrane region. The hinge region is an amino acid segment that is generally present between the two domains of a protein and can allow for the flexibility of the protein and the relative movement of the two domains. The hinge region can be a hinge region of a naturally occurring protein or a portion thereof. The hinge region of an antibody (such as an IgG, IgA, IgM, IgE or IgD antibody) can also be used for the chimeric antigen receptor described herein. Non-naturally occurring peptides can also be used as the hinge region of the chimeric antigen receptor described herein. In some embodiments, the hinge region is a peptide linker. Preferably, the hinge region is derived from CD8α. Also preferably, the CD8α hinge region has the amino acid sequence shown in SEQ ID NO:38.

[0079] The transmembrane region of the chimeric antibody receptor can form an alpha helix, a complex of more than one alpha helix, a beta barrel, or any other stable structure capable of spanning the phospholipid bilayer of a cell. The transmembrane region can be of natural or synthetic origin. The transmembrane region can be derived from the alpha, beta, or zeta chain of CD3ε, CD4, CD5, CD8α, CD9, CD16, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, or a T cell receptor. Preferably, the transmembrane region is derived from CD8α. Preferably, the CD8α transmembrane region has the amino acid sequence shown in SEQ ID NO: 40.

[0080] Preferably, the intracellular region of the chimeric antigen receptor comprises a signal transduction domain and / or a costimulatory signal transduction domain. The number of the signal transduction domain and / or the costimulatory signal transduction domain can be one or more.

[0081] The intracellular signaling region is responsible for the activation of at least one normal effector function of the immune effector cell expressing the chimeric antigen receptor. For example, the effector function of the T cell can be cytolytic activity or helper activity, including cytokine secretion. Although the entire intracellular signaling region can generally be utilized, in many cases, it is not necessary to use the entire chain. Insofar as a truncated portion of the intracellular signaling region is used, such a truncated portion can be used in place of the entire chain as long as it transduces the effector function signal. Therefore, the intracellular signaling region includes any truncated form of the intracellular signaling region that is sufficient to transduce the effector function signal. In some embodiments, the signaling region is derived from at least one of CD3ζ, FcRγ (FCER1G), FcRβ (FcεRib), CD3γ, CD3δ, CD3ε, CD5, CD22, CD137, CD79a, CD79b, and CD66d. Preferably, the intracellular region is derived from the human CD3ζ intracellular region. Furthermore, the human CD3ζ intracellular region has the amino acid sequence set forth in SEQ ID NO: 44.

[0082] In addition to the stimulation of antigen-specific signals, many immune effector cells also need costimulation to promote cell proliferation, differentiation and survival, and the effector functions of activated cells." costimulatory signaling conduction zone " can be the cytoplasmic part of costimulatory molecules.Term " costimulatory molecules " refers to the associated binding partner on immune cells (such as T cells), and the associated binding partner specifically binds to costimulatory ligands, so as to mediate costimulatory responses by immune cells, such as but not limited to proliferation and survival.Costimulatory signaling conduction zone can be derived from CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54, CD83, OX40, CD137, CD134, CD150, CD152, CD223, CD270, PD-L2, PD-L1, CD278, DAP10, LAT, NKD2C, SLP76, TRIM, FcεRIγ, MyD88 and 4-1BB at least one intracellular signaling zone. In some embodiments, the costimulatory signaling region is derived from 4-1BB. In some embodiments, the 4-1BB costimulatory signaling region comprises the amino acid sequence set forth in SEQ ID NO: 42.

[0083] Preferably, the nucleotide sequence of the CAR is shown as SEQ ID NO: 20, and its coding sequence is shown as SEQ ID NO: 21.

[0084] In order to solve the various side effects associated with CAR-T cell therapy and increase the safety of CAR-T cell therapy, the chimeric antigen receptor CAR designed by the inventors further includes a "suicide switch" RQR8 molecule, which has an amino acid sequence shown in SEQ ID NO: 47, and its coding sequence is shown in SEQ ID NO: 48. The RQR8 molecule is fused with the intracellular signaling domain CD3ζ in the CD7-CAR structure with a T2A connecting peptide with a self-cleavage function. Preferably, the RQR8 molecule carries two CD20 antigen epitopes, and uses anti-CD20 rituximab (Rituximab) to target CD20, activate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC), and induce T cell apoptosis. When necessary, for example, rituximab can be used to eliminate CAR-T cells, thereby increasing the safety of CAR-T cell therapy.

[0085] The present invention provides an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof, or blocking molecule, or chimeric antigen receptor as described above.

[0086] The present invention provides a vector comprising the isolated nucleic acid described herein. The vector can be an expression vector or a cloning vector. In some embodiments, the vector is a viral vector. Viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, vaccinia vectors, herpes simplex virus vectors, and their derivatives.

[0087] The present invention provides a host cell comprising the above-mentioned vector. Suitable host cells for cloning or expressing DNA are prokaryotic cells, yeast cells, or higher eukaryotic cells. Examples of commonly used prokaryotic host cells include Escherichia coli, Bacillus subtilis, etc. Commonly used eukaryotic host cells include yeast cells, insect cells, mammalian cells, etc.

[0088] The present invention provides a method for preparing an anti-human CD7 chimeric antigen receptor CAR, which comprises culturing the above-mentioned host cells. Preferably, the culture conditions of the preparation method are sufficient to enable the host cells to express the anti-human CD7 chimeric antigen receptor CAR.

[0089] The present invention provides an immune effector cell, which expresses the above-mentioned antibody or antigen-binding fragment thereof that specifically binds to CD7, or a blocking molecule, or a chimeric antigen receptor CAR against human CD7.

[0090] In the present invention, "immune effector cells" are immune cells that can perform immune effector functions. In some embodiments, immune effector cells express at least FcγRIII and perform ADCC effector functions. Examples of immune effector cells that mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells, neutrophils and eosinophils. Preferably, the immune effector cells are selected from: at least one of immune cells, T lymphocytes, NK cells, peripheral blood mononuclear cells (PBMC) and hematopoietic stem cells cultured and differentiated by pluripotent stem cells or embryonic stem cells. More preferably, the immune effector cells are T lymphocytes (same as T cells). In some embodiments, T cells can be CD4+ / CD8-, CD4- / CD8+, CD4+ / CD8+, CD4- / CD8- or a combination thereof. In some embodiments, T cells produce IL-2, IFN and / or TNF when expressing chimeric antigen receptors and binding to target cells. In some embodiments, CD8+ T cells lyse antigen-specific target cells when they express a chimeric antigen receptor and bind to the target cell.

[0091] The present invention provides a method for preparing the immune effector cells, comprising infecting the immune effector cells with the isolated nucleic acid or the vector described herein. Preferably, the present invention prepares genetically modified immune effector cells by introducing a chimeric antigen receptor into immune effector cells (such as T cells).

[0092] It should be noted that the method for introducing nucleic acid or vector into mammalian cells is known in the art, and the vector can be transferred to immune effector cells by physical, chemical or biological methods. The physical method for introducing vector into immune effector cells includes calcium phosphate precipitation, liposome transfection, particle bombardment, microinjection, electroporation, etc. The chemical means for introducing nucleic acid or vector into immune effector cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads and lipid-based systems (including oil-in-water emulsions, micelles, mixed micelles and liposomes). The exemplary colloidal system used as an in vitro delivery vehicle is liposomes (such as artificial membrane vesicles). The biological method for introducing nucleic acid or vector into immune effector cells includes the use of DNA and RNA vectors. Viral vectors have become the most widely used method for inserting genes into mammals, such as human cells. In some embodiments, transduced or transfected immune effector cells are propagated in vitro after introducing nucleic acid or vector.

[0093] In some embodiments, the preparing further comprises further evaluating or screening the transduced or transfected immune effector cells to select engineered immune effector cells.

[0094] The present invention further provides a drug or pharmaceutical composition, comprising: the antibody or antigen-binding fragment thereof that specifically binds to CD7, the isolated nucleic acid, the vector, the chimeric antigen receptor CAR, the isolated nucleic acid, the anti-human CD7 chimeric antigen receptor CAR obtained by the preparation method of the chimeric antigen receptor CAR, the immune effector cell, and at least one of the immune effector cells prepared by the preparation method of the immune effector cell.

[0095] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[0096] Pharmaceutical compositions can be prepared by mixing an active agent of the desired purity with an optional pharmaceutically acceptable carrier in the form of a lyophilized formulation or an aqueous solution. The pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and may include at least one of a buffer, an antioxidant, a preservative, an isotonic agent, a stabilizer, and a surfactant. In addition, in order for the pharmaceutical compositions to be useful for in vivo administration, they must be sterile. Pharmaceutical compositions can be sterilized by filtration through a sterile filtration membrane.

[0097] In some embodiments, the pharmaceutical composition may contain at least one additive selected from the group consisting of a cytotoxic agent, a chemotherapeutic agent, a cytokine, an immunosuppressant, a growth inhibitor, and an active pharmaceutical ingredient required for the specific indication to be treated. The specific amount of the additive may be adjusted according to actual needs.

[0098] The present invention also provides the use of a reagent in the preparation of a drug or pharmaceutical composition for treating or improving cancer, wherein the reagent is selected from: the antibody or antigen-binding fragment thereof that specifically binds to CD7, the isolated nucleic acid, the vector, the host cell, the anti-human CD7 chimeric antigen receptor CAR, the anti-human CD7 chimeric antigen receptor CAR obtained by the preparation method of the anti-human CD7 chimeric antigen receptor CAR, the immune effector cell, and at least one of the immune effector cells prepared by the preparation method of the immune effector cell.

[0099] Preferably, the treating or improving cancer refers to stimulating or improving the immune function of cancer patients.

[0100] Preferably, the cancer is a cancer associated with CD7 expression.

[0101] As used herein, "cancer associated with CD7 expression" refers to a disease directly or indirectly caused by abnormal CD7 expression, and typically refers to a disease caused by overexpression of CD7. Preferably, the cancer or tumor is a hematological malignancy. Further preferably, the hematological malignancy is a T-cell-related tumor, which includes leukemia, lymphoma, and myeloma.

[0102] The present invention also provides a method for treating / preventing cancer, which includes the step of administering a therapeutically effective amount of a drug to a subject in need, wherein the drug includes: the antibody or antigen-binding fragment thereof that specifically binds to CD7, the isolated nucleic acid, the vector, the host cell, the anti-human CD7 chimeric antigen receptor CAR, the anti-human CD7 chimeric antigen receptor CAR prepared by the preparation method of the anti-human CD7 chimeric antigen receptor CAR, the immune effector cell, and at least one of the immune effector cells prepared by the preparation method of the immune effector cell.

[0103] As used herein, the terms "subject" and "patient" are used interchangeably herein to refer to any animal that may be in need of the antibody-related formulations or medicaments or treatments described herein. Subjects and patients therefore include, but are not limited to, primates (including humans), canines, felines, mice, and other mammalian subjects. Preferably, the subject is human.

[0104] In the present invention, the term "treatment" refers to therapeutic treatment and preventive or prophylactic measures, the purpose of which is to prevent or slow down (reduce) the progression of undesirable physiological changes or disorders, such as autoimmune diseases. Beneficial or desired clinical results include, but are not limited to, the following detectable or undetectable results, including alleviation of symptoms, reduction in disease severity, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and relief (whether partial or complete). "Treatment" also means the extended survival period compared to the expected survival period when not receiving treatment. Those in need of treatment include those who already have a disease or disorder, as well as those who are prone to a disease or disorder, or those who need to prevent the disease or disorder.

[0105] As used herein, the term "effective amount" refers to the amount of a drug or pharmaceutical agent that elicits a biological or pharmaceutical response of a tissue, system, animal or human being, such as that pursued by a researcher or clinician. In addition, the term "therapeutically effective amount" refers to an amount that causes improved treatment, cure, prevention or alleviation of a disease, condition or side effect, or an amount that reduces the rate of progression of a disease or condition, compared to a corresponding subject that has not received the amount. The term also includes within its scope an amount that effectively enhances normal physiological function. Typically, the effective amount herein varies according to various factors, such as a given drug or compound, pharmaceutical preparation, route of administration, type of disease or condition, subject being treated, etc., but can still be routinely determined by those skilled in the art. The effective amount of the compound of the present invention can be easily determined by those skilled in the art by conventional methods known in the art.

[0106] The present invention also provides the use of the antibody or antigen-binding fragment thereof, or the blocking molecule, or the chimeric antigen receptor, or the immune effector cell according to the present invention in combination with other drugs. Preferably, the other drug includes a diagnostic agent, a prophylactic agent, and / or a therapeutic agent. Further preferably, the other drug is a CD20-targeted antibody drug, including but not limited to rituximab, atuzumab, ofatumumab, ibritumomab, and the like.

[0107] Example 1

[0108] This example is the preparation of mouse monoclonal antibodies against CD7 antigen.

[0109] In this example, five peptides were designed and synthesized for the CD7 antigen and used to immunize BALB / c mice. After cell fusion, primary screening, and secondary screening, a positive clone was obtained that recognized both the peptide BST001-2 and the CD7 recombinant protein. The clone number of this positive hybridoma cell line was 5B5.

[0110] The amino acid sequence of the CD7 antigen precursor protein is shown in SEQ ID NO: 1, wherein amino acid residues 26-180 represent the CD7 antigen extracellular domain. The CD7 recombinant protein is a recombinant human CD7 protein (with a His tag, a product of Biopsies, catalog number 11028-H08H), and its amino acid sequence represents the CD7 antigen extracellular domain sequence, as shown in SEQ ID NO: 2.

[0111] The amino acid sequences of the five synthetic antigen peptides used to immunize mice correspond to five amino acid residues in the extracellular domain of the CD7 antigen. The specific sequences are shown in Table 1:

[0112] Table 1. Amino acid sequences of 5 synthetic peptides

[0113] Polypeptide numbering Polypeptide sequence corresponds to the sequence number in the sequence listing BST001-1AQEVQQSPHC SEQ ID NO: 3 BST001-2CEDGVVPTTDRRFRGRID SEQ ID NO: 4 BST001-3TEEQSQGWHRC SEQ ID NO: 5 BST001-4HRLQLSDTGTYTC SEQ ID NO: 6 BST001-5CPPTGSALPD SEQ ID NO: 7

[0114] Of the five peptides, the first amino acid at the N-terminus of BST001-2 and BST001-5 (in bold in the table) is an added cysteine ​​(Cys), while the C-terminal amino acid of peptides BST001-1, BST001-3, and BST001-4 is a Cys. Each of the five peptides was conjugated to the carrier protein KLH (Keyhole Limpet Hemocyanin) via the Cys residue at the N-terminus or C-terminus and used as an immunogen to immunize a group of mice. Tail blood samples from the immunized mice were then analyzed for monoclonal antibody screening.

[0115] The mouse monoclonal antibody of the present invention is a monoclonal antibody that recognizes polypeptide BST001-2 and CD7 antigen protein, obtained by immunization with polypeptide BST001-2 as an immunogen. The following is a specific description using polypeptide BST001-2 as an example.

[0116] 1.1 Immunization of mice and evaluation of immune responses

[0117] BST001-2-KLH was mixed with adjuvants CFA and AD11.15, respectively, to prepare immunogens. Three BALB / c mice were immunized. Tail blood was drawn from the mice on the 14th day after immunization, and the antibody titer in the serum was evaluated using an indirect ELISA method.

[0118] The specific operating steps of the indirect ELISA method are:

[0119] (1) Coat the ELISA plate with BST001-2 peptide: add 100 μL of BST001-2 peptide (concentration 1 μg / mL) to each well and react at 4°C overnight;

[0120] (2) Wash the plate three times with PBS solution and block with 5% milk-PBS at room temperature for 1 hour;

[0121] (3) Wash the plate once with PBS solution, add mouse tail blood diluted with 5% milk-PBS solution, and react at room temperature for 1 hour;

[0122] (4) Wash the plate three times with PBS solution, pat dry, and add 1:2000 diluted HRP-labeled goat anti-mouse IgG (Fc) secondary antibody for reaction at room temperature for 1 hour;

[0123] (5) Wash the plate five times with PBS solution, pat dry, add equal volumes of solution A and solution B, and react at room temperature in the dark for 20 min;

[0124] (6) Add 50 μL of stop solution, mix well and read the OD on a microplate reader. 450 value.

[0125] The results of indirect ELISA evaluation of mouse tail blood on day 14 after immunization are shown in Table 2. The results show that the antibody titers in the tail blood of all three mice reached above 1:10,000, and mouse #1 was subsequently selected for cell fusion in step 1.2 below.

[0126] Table 2. ELISA evaluation of antibody titers in mouse tail blood on day 14 after immunization

[0127]

[0128] Note: The negative control NC is 5% milk-PBS.

[0129] 1.2 Cell fusion and screening of hybridoma cell lines

[0130] Based on the ELISA results of tail blood from mice in Table 2, splenocytes from mouse #1 were fused with SP2 / 0 myeloma cells 21 days after immunization. Ten days after fusion, 564 monoclonal cells were isolated and cultured in 96-well plates. After 7 days of culture, the supernatants of the 564 monoclonal cells in the 96-well plates were evaluated using the indirect ELISA method described in step 1.1 to screen for hybridoma cell lines that secrete monoclonal antibodies that recognize the CD7 antigen polypeptide. Seven positive clones were initially selected.

[0131] The 7 positive clones were further screened using the indirect ELISA method described in step 1.1, and the results are shown in Table 3.

[0132] Table 3. ELISA rescreening confirmation of mouse fusion-positive clones

[0133]

[0134] Note: Negative control NC is 5% Milk-PBS; positive control PC is 1# mouse heart blood, diluted 1:500.

[0135] From the rescreening results in Table 3, a strongly positive hybridoma cell line 5B5 that recognized the BST001-2 polypeptide was obtained.

[0136] 1.3 Reconfirmation of the Strongly Positive Hybridoma Cell Line 5B5

[0137] The indirect ELISA method described in step 1.1 was used to perform another confirmation experiment on the supernatant of the expanded culture of the strongly positive hybridoma clone numbered 5B5. The results are shown in Table 4.

[0138] Table 4. ELISA reconfirmation of 5B5 positive clones

[0139] 5B55B5NCNCPCPC2.6772.7490.3160.1072.7672.677

[0140] Note: NC is the negative control 5% Milk-PBS; PC is the positive control 1# mouse heart blood, used at a dilution of 1:500.

[0141] The indirect ELISA method described in step 1.1 was further used to coat the ELISA plate with the aforementioned CD7 recombinant protein (with his tag) instead of the BST001-2 polypeptide, and the cell supernatant of the 5B5 clone was detected. The results are shown in Table 5.

[0142] Table 5. Competitive ELISA detection of 5B5 positive clones

[0143] 5B5NCPC2.7820.0472.6362.7590.0432.629

[0144] Note: Negative control NC is 5% Milk-PBS; positive control PC is mouse monoclonal antibody against His tag of CD7 recombinant protein.

[0145] From the results in Tables 4 and 5 above, it can be seen that the cell supernatant of the 5B5 clone strain produced a strong recognition reaction with both the CD7 BST001-2 polypeptide antigen and the CD7 recombinant protein antigen, and 5B5 is the desired hybridoma cell line capable of producing anti-CD7 monoclonal antibodies.

[0146] 1.4 Cloning and sequencing of the variable regions of the monoclonal antibody from the hybridoma cell line 5B5

[0147] The 5B5 hybridoma cell line was cultured, the cells were collected, and RNA was extracted. The cDNA sequence encoding the anti-CD7 monoclonal antibody was obtained by RT-PCR. The variable regions of the heavy and light chains were cloned by PCR, and the PCR products were ligated into a T-vector. The sequences of the heavy chain variable region (VH) and light chain variable region (VL) of the anti-CD7 monoclonal antibody were obtained by sequencing and further aligned and confirmed using the Uniprot database.

[0148] The nucleotide sequence of the obtained VH is shown in SEQ ID NO: 8, and the amino acid sequence encoded by it is shown in SEQ ID NO: 9; the nucleotide sequence of the obtained VL is shown in SEQ ID NO: 10, and the amino acid sequence encoded by it is shown in SEQ ID NO: 11.

[0149] The obtained VH and VL amino acid sequences were further analyzed to identify the complementarity determining regions (CDRs). The results are shown in Table 6.

[0150] Table 6. CDR analysis of the VH and VL domains of the anti-CD7 5B5 monoclonal antibody

[0151]

[0152]

[0153] Example 2

[0154] This example is the construction of CD7-Blocker and CD7-CAR lentiviral expression vectors.

[0155] The CD7 blocking molecules CD7-Blocker and CD7-CAR were constructed into the third-generation lentiviral expression plasmids respectively using conventional technical means in the art. The plasmid is pCDH-EF1(X6)-MCS-T2A-Puro, and its map is shown in Figure 1. The vector linearization restriction sites are XbaI and SalI, and the DNA sequences of CD7-Blocker and CD7-CAR (including the N-terminal KOZAC sequence) are inserted between the two restriction sites. The molecular structure of CD7-Blocker is shown in Figure 2. The CD7-Blocker molecule consists of three parts: CD8a signal peptide SP, anti-CD7 scFv composed of VL and VH connected by a (G4S)3 linker, and ER Retention Domain (endoplasmic reticulum localization domain). The KOZAK sequence that promotes expression is inserted at the front end of SP. Its full-length amino acid sequence is shown in SEQ ID NO: 18, and its full-length DNA sequence is shown in SEQ ID NO: 19 (including the N-terminal KOZAC sequence).

[0156] The molecular structure of CD7-CAR is shown in Figure 3. It consists of an anti-CD7 scFv consisting of a CD8a signal peptide SP, a (G4S)3 linker connecting VL and VH, a CD8a hinge region, a CD8a transmembrane region, and two intracellular signaling domains, 4-1BB and CD3ζ. A cellular "suicide switch" RQR8 molecule is then fused via a self-cleaving T2A linker peptide. A KOZAK sequence is also inserted at the front of SP to promote expression. Its full-length amino acid sequence is shown in SEQ ID NO: 20, and its full-length DNA sequence is shown in SEQ ID NO: 21 (including the N-terminal KOZAK sequence). The nucleotide coding sequences for VH and VL in the CD7-Blocker and CD7-CAR molecular structures are shown in SEQ ID NO: 22 and SEQ ID NO: 23, respectively. They are derived from the mouse VH sequence (SEQ ID NO: 8) and VL sequence (SEQ ID NO: 10), respectively, optimized according to human codons. VL and VH were fused through the linker (G4S)3 to form anti-CD7 scFv.

[0157] CD7-Blocker is composed of anti-CD7 scFv and ER localization signal KDEL connected by a linker (G4S) 2, and (G4S) 2-KDEL constitutes the ER Retention Domain (endoplasmic reticulum localization domain). The ER Retention Domain can localize the anti-CD7 scFv to the ER reticulum. The CD7 antigen molecule is intercepted by the anti-CD7 scFv in the ER reticulum during the secretory pathway and cannot be normally localized to the cell surface, thereby avoiding "cannibalism" between CD7-CAR-T cells. In another embodiment, the linker connecting the anti-CD7 scFv and the ER localization signal is the myc sequence EQKLISEEDL (SEQ ID NO: 33).

[0158] The sequence numbers corresponding to the amino acid and nucleotide sequences of each fragment in the CD7-Blocker and CD7-CAR molecular structures are shown in Table 7, where SP is the CD8a signal peptide, CD8H is the CD8a hinge region, CD8TM is the CD8a transmembrane region, and 4-1BB and CD3ζ are both intracellular signaling domains.

[0159] Table 7. Correspondence of fragment sequences in the CD7-Blocker and CD7-CAR molecular structures

[0160] Fragment name Amino acid sequence Nucleotide sequence VH domain of anti-CD7 scFv SEQ ID NO: 9 SEQ ID NO: 22 VL domain of anti-CD7 scFv SEQ ID NO: 11 SEQ ID NO: 23 KOZAK / SEQ ID NO: 24 (G4S) 3 linker SEQ ID NO: 25 SEQ ID NO: 26 ER localization signal KDEL SEQ ID NO: 27 SEQ ID NO: 28 (G4S) 2 linker SEQ ID NO: 29 SEQ ID NO: 30 ER Retention Domain SEQ ID NO: 31 SEQ ID NO: 32 Myc linker SEQ ID NO: 33 SEQ ID NO: 34 SP (CD8a signal peptide) SEQ ID NO: 35 SEQ ID NO: 36 CD8H (CD8a hinge region) SEQ ID NO: 37 SEQ ID NO: 38 CD8TM (CD8a transmembrane region) SEQ ID NO: 39 SEQ ID NO: 40 4-1BB SEQ ID NO: 41 SEQ ID NO: 42 CD3ζ SEQ ID NO: 43 SEQ ID NO:44T2ASEQ ID NO:45SEQ ID NO:46RQR8SEQ ID NO:47SEQ ID NO:48CD20 EpitopeSEQ ID NO:49SEQ ID NO:50

[0161] CAR-T cell therapy is usually accompanied by a variety of toxic side effects. In order to increase the safety of CAR-T cell therapy, the present invention incorporates a "suicide switch" RQR8 molecule (SEQ ID NO: 47, SEQ ID NO: 48) into the CD7-CAR molecular structure. The RQR8 molecule is fused with the intracellular signaling domain CD3ζ in the CD7-CAR structure with a T2A connecting peptide with self-cleavage function. The RQR8 molecule carries two CD20 antigen epitopes. Using anti-CD20 rituximab (Rituximab) to target CD20, it activates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC), which can induce T cell apoptosis. When necessary, rituximab can be used to eliminate CAR-T cells, thereby increasing the safety of CAR-T cell therapy.

[0162] Lentiviral packaging uses a conventional four-plasmid system in the field, in which the three auxiliary plasmids are pMDLg / pRRE, pRSV-Rev, and pMD2.G. 293T cells are used as lentiviral packaging cells. The plasmid dosage ratio of 293T cells co-transfected with lentiviral expression plasmids carrying CD7-Blocker or CD7-CAR and pMDLg / pRRE, pRSV-Rev, and pMD2.G is 7.5:9:9:3.5; for T75 cell culture flasks, the four plasmid dosages are 7.5ug, 9ug, 9ug, and 3.5ug, respectively. The amount of transfection reagent PEI (ug) is 3 times the total amount of the four plasmids. For T75 culture flasks, the PEI dosage is 87ug (1ug / ul, 87ul).

[0163] 48 hours after the four plasmids were co-transfected into 293T cells, the cell culture medium was collected and centrifuged (2000 rpm, 15 min). The supernatant was collected and filtered through a 0.45 μm filter. The supernatant was concentrated by ultracentrifugation (20000 rpm, 2 h). The virus pellet was then resuspended in the corresponding volume of culture medium according to the dilution factor, aliquoted, and stored at -80°C.

[0164] For CD7-Blocker lentivirus, the lentiviral titer is directly measured using a lentiviral vector HIV P24 rapid test card. For CD7-CAR lentivirus titer determination, the lentivirus is serially diluted and then transfected into 293T cells. After 48 hours, the transfection efficiency is measured by flow cytometry, and the lentiviral activity titer is calculated.

[0165] Example 3

[0166] This example is the affinity identification of Anti-CD7 scFv and CD7 antigen molecules.

[0167] 293T cells were transduced with CD7-CAR lentivirus, and the CD7-CAR positivity rate in 293T cells and the ratio of 293T cells binding to CD7 antigen protein were detected by flow cytometry. The affinity ratio of CD7-CAR to CD7 antigen protein in CD7-CAR-293T cells was calculated to represent the affinity of Anti-CD7 scFv to CD7 antigen molecules.

[0168] The CD7 antigen protein is the recombinant human CD7 protein with a His tag in Example 1. During flow cytometry detection, the CD7 antigen protein is first incubated with CD7-CAR-293T cells, and then a fluorescently labeled anti-His mouse monoclonal antibody is used to detect the CD7 antigen protein bound to 293T cells.

[0169] The 293T cells transduced with CD7-CAR lentivirus were subjected to two flow cytometry tests, and the results are shown in Table 8.

[0170] Table 8. Affinity detection of Anti-CD7 scFv and CD7 antigen molecules

[0171]

[0172] The results in Table 8 show that the average affinity between CD7-CAR and CD7 antigen molecules is 99.51%, indicating that anti-CD7 scFv has extremely strong affinity with CD7 antigen molecules.

[0173] Example 4

[0174] This example shows the blocking effect of CD7-Blocker on CD7 molecules on the surface of Jurkat cells.

[0175] Jurkat cells were transduced with the CD7-Blocker lentivirus. Four days later, the CD7 positivity rate on the surface of Jurkat cells was determined by flow cytometry. The results are shown in Table 9 and Figure 4. The CD7 positivity rate on the surface of control Jurkat cells without CD7-Blocker was 92.45%. At an MOI of 10, the CD7 positivity rate on the surface of Jurkat cells dropped to 0.09% (see Figure 4D). At this point, the blocking efficiency of D7 Blocker on the surface of Jurkat cells reached its limit of 99.90%. At an MOI of 5 (see Figure 4C), the blocking efficiency was close to its limit, and further increasing the MOI to 15 (see Figure 4E) had no significant effect on the blocking efficiency. These results demonstrate that CD7-Blocker can almost completely block the expression of CD7 molecules on the surface of Jurkat cells.

[0176] Table 9. Blocking efficiency of CD7-Blocker on CD7 molecules on the surface of Jurkat cells

[0177] Transduction MOI 02.55 1015 CD7 positive rate (%) 92.45 2.30.58 0.09 0.14 CD7 positive rate Flow cytometry Figure 4A Figure 4B Figure 4C Figure 4D Figure 4ECD7 blocking efficiency (%) 97.599.3799.9099.89

[0178] Example 5

[0179] This example shows the blocking effect of CD7-Blocker on CD7 molecules on the surface of T cells.

[0180] After thawing, frozen PBMCs were activated with CD3 / CD28 antibody magnetic beads (activation time point was marked as D0). One day after activation (D1), CD7-Blocker lentivirus was transfected (BT experimental group), and two days after activation (D2), CD7 CAR lentivirus was transfected. The experiment was divided into four groups: untransfected control group (NT group), transfected with CD7-Blocker virus alone (BT group), co-transfected with CD7-Blocker and CD7 CAR virus on the basis of NT (B-CAR-T group), and transfected with CD7 CAR virus alone (CAR-T group). The MOI value of viral transfection was 5. After transfection, the positive rate of CD7 antigen molecules on the cell surface was detected by flow cytometry on D6 (6 days after activation, 5 days after Blocker virus transfection, and 4 days after CAR virus transfection). The results are detailed in Table 10 and Figure 5.

[0181] It can be seen that under the experimental conditions of this example, the blocking efficiency of CD7-Blocker (BT group) on CD7 molecules reached 91.12%, CD7-CAR alone (CAR-T group) had almost no effect on the cell surface expression of CD7 molecules, and the blocking efficiency of CD7-Blocker & CD7-CAR (B-CAR-T group) on CD7 molecules reached 93.67%.

[0182] Table 10. Blocking efficiency of CD7-Blocker on CD7 molecules on T cell surface

[0183] NTB-TB-CAR-TCAR-TCD7 positive rate (%) 94.448.345.9893.58

[0184] CD7 positive rate flow cytometry graph Figure 5A Figure 5B Figure 5C Figure 5CCD7 blocking efficiency (%) 91.1293.670.91

[0185] Example 6

[0186] This example shows the effect of CD7-Blocker on T cell proliferation.

[0187] This example detects and compares the in vitro expansion of four groups of T cells: control T cells (NT group) that are not transfected with the CD7-Blocker virus, CD7-Blocker-T cells (BT group) that are transfected only with the CD7-Blocker lentivirus, CD7-CAR-T cells (CAR-T group) that are transfected only with the CD7-CAR lentivirus, and CD7-Blocker-CAR-T cells (B-CAR-T group) that are transfected with both the CD7-Blocker virus and the CD7-CAR virus. The time points for viral transfection of each group of cells are as in Example 4.

[0188] Culture time description: After one day of cryopreserved PBMC resuscitation, CD3 / CD28 antibody magnetic beads were added for activation. The activation time point was designated as D0. The time points one and two days after activation were designated as D1 and D2, respectively. The surface CD7 molecule positivity and CAR positivity rates of T cells in the four groups are shown in Table 11 and Figure 6. The cell expansion times are shown in Table 12, and the cell expansion curves are shown in Figure 7.

[0189] These results show that compared with control T cells, BT cells transfected with CD7-Blocker virus alone and B-CAR-T cells co-transfected with CD7-Blocker virus and CD7-CAR virus can all expand normally, while CAR-T cells transfected with CD7-CAR lentivirus alone are difficult to expand in vitro. This phenomenon shows that blocking CD7 molecules will basically not affect the normal expansion of T cells, while CAR-T cells that have not been blocked by CD7 molecules will express CD7 molecules on their surface, which will lead to CD7-CAR-T cell cannibalism.

[0190] Table 11. CD7 molecule positive rate and CAR positive rate

[0191]

[0192] Table 12. Cell expansion fold (relative to D2)

[0193] Day267912NT1.0013.8517.0436.4633.91B-T1.009.1210.1214.8823.81B-CAR-T1.005.086.0511.6220.92

[0194] Example 7

[0195] This example is an in vitro killing experiment of CD7-CAR-T cells on CD7-positive target cells.

[0196] To further verify the specificity of CD7-CAR-T cells in killing CD7-positive target cells, a CD7-overexpressing U87-CD7-eGFP cell line was constructed using CD7-negative U87 cells, and the killing effect of CD7-CAR-T cells on CD7-positive target cells U87-CD7-eGFP was analyzed using RTCA instrument.

[0197] The CD7 antigen molecule coding sequence used to construct the U87-CD7-eGFP cell line is the DNA coding sequence for the CD7 antigen precursor protein (SEQ ID NO: 51). The amino acid sequence of the eGFP molecule used is shown in SEQ ID NO: 52, and its DNA coding sequence is shown in SEQ ID NO: 53. The CD7 molecule and the eGFP molecule are connected by a self-cleaving linker peptide T2A (SEQ ID NO: 45, SEQ ID NO: 46). The CD7-T2A-eGFP construct is added to the N-terminus of the KOZAK sequence and inserted between the XbaI and SalI restriction sites of the lentiviral vector pCDH-EF1(X6)-MCS-T2A-Puro to construct a CD7 overexpression lentiviral vector. The lentiviral CD7-T2A-eGFP was transduced into U87 cells according to conventional methods, and eGFP was used as a screening and detection marker for the transduced cells.

[0198] Because CD7-CAR-T cells have a fratricidal phenomenon, the effector cells used in the killing experiment are CD7-Blocker-CAR-T cells (referred to as B-CAR-T) whose surface expression of CD7 molecules is blocked by CD7-Blocker. Its CAR positive rate is 45.79% and the surface CD7 molecule positive rate is 5.97%. The control T cells for the killing experiment are CD7-Blocker-T (referred to as BT) cells, whose surface CD7 molecule positive rate is 8.35%. The CD7 surface molecule positive rate of unblocked T cells is 94.44%. The above positive rate data are shown in Table 11 and Figure 6 in Example 6.

[0199] Killing experiment curves are shown in Figures 8 and 9. Time point 0.0 marks the start of target cell culture. Effector cells were added to the target cell culture at 28 hours of target cell culture. The co-culture effector-target ratio was B-CAR-T (or control BT): U87-CD7-eGFP (or control U87) = 4:1. The entire experiment lasted 96 hours.

[0200] Figure 8 shows the killing curve of two T cells co-cultured with positive target cells U87-CD7-eGFP. It can be seen that only B-CAR-T has a significant killing effect on CD7 positive target cells U87-CD7-eGFP. Figure 9 shows the killing curve of two T cells co-cultured with negative target cells U87. It can be seen that B-CAR-T has only a slight killing effect on U87. These results show that CD7-CAR-T cells with CD7 surface molecules blocked by CD7 Blocker have a significant and specific killing effect on CD7 positive target cells. The present invention provides beneficial CAR-T cells for the next step of clinical application of cell therapy.

[0201] In order to further analyze the killing efficiency of B-CAR-T on target cells, the cell index values ​​at both ends of the early co-culture period (Cell Index at: 60:04:20 & at: 30:33:52) were intercepted. The killing efficiency is shown in Figure 10. The BT group was co-cultured with control CD7-Blocker-T cells and U87-CD7-eGFP cells, and the BC-T group was co-cultured with CD7-Blocker-CAR-T cells and U87-CD7-eGFP cells. It can be seen that at E:T = 4:1, compared with the control BT cells, B-CAR-T has a high killing efficiency against CD7-positive target cells.

[0202] Although the present invention has been described with reference to exemplary embodiments, it should be understood that the invention is not limited to the disclosed exemplary embodiments. Various modifications and variations may be made to the exemplary embodiments of the present specification without departing from the scope or spirit of the present invention. The scope of the claims is to be given the broadest interpretation so as to encompass all such modifications and equivalent structures and functions.

Claims

1. An antibody or an antigen-binding fragment thereof, characterized in that The heavy chain variable region comprises the antigen complementary determining regions CDR1, CDR2 and CDR3 having the amino acid sequences shown in SEQ ID NOs.: 12-14; and A light chain variable region having antigenic complementarity determining regions CDR1, CDR2 and CDR3 of the amino acid sequences shown in SEQ ID NOs.: 15-17.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody has any one of the amino acid sequences shown in (I), (II) or (III): (I) the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 9 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 11; (II) an amino acid sequence having at least 90%, preferably at least 95%, even more preferably at least 98%, and most preferably at least 99% homology to the amino acid sequence shown in SEQ ID NO.: 9 and 11; (III) amino acid sequences obtained by modifying, substituting, deleting or adding one or more amino acids to the amino acid sequences shown in SEQ ID NOs.: 9 and 11; The amino acid sequence has the activity of an antibody against the tumor surface antigen CD7.

3. The antibody or antigen-binding fragment thereof according to claim 2, wherein The antibody comprises at least one of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody or a bispecific antibody; and the antigen-binding fragment comprises at least one of a Fab fragment, a Fab', a F(ab')2 fragment, a single-chain variable fragment scFv, a scFv-Fc fragment or a single-chain antibody ScAb.

4. A CD7 blocking molecule, characterized in that It includes: a. an antibody or antigen-binding fragment thereof according to any one of claims 1 to 3; and b. Endoplasmic reticulum localization domain.

5. A chimeric antigen receptor, characterized in that It includes: 1) an antigen-binding domain that recognizes the CD7 antigen, wherein the antigen-binding domain comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3; 2) a transmembrane domain; and 3) intracellular signaling domain; Preferably, further comprising a hinge region; Preferably, it further comprises a suicide switch molecule; Preferably, further comprising an intracellular costimulatory domain; Preferably, the transmembrane domain is selected from the group consisting of polypeptides CD28, NKp30, CDS, DAP10, 4-1BB, DAP12, CD3C, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6 , CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96, CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, or a combination thereof; Preferably, the intracellular signaling domain is selected from the group consisting of: CD8, CD3ζ, CD3δ, CD3γ, CD3ε, FcγRI-γ, FcγRIII-γ, FcεRIβ, FcεRIγ, DAP10, DAP12, CD32, CD79a, CD79b, CD28, CD3C, CD4, b2c, CD137 (4-1BB), ICOS, CD27, CD28δ, CD80, NKp30, OX40, or a combination thereof.

6. An isolated nucleic acid molecule, characterized in that It encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the blocking molecule according to claim 4, or the chimeric antigen receptor according to claim 5.

7. A carrier, characterized in that It comprises the nucleic acid molecule according to claim 6.

8. A host cell, characterized in that It comprises the vector according to claim 7.

9. An immune effector cell, characterized in that It expresses the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the blocking molecule according to claim 4, or the chimeric antigen receptor according to claim 5; Preferably, the immune effector cells are selected from at least one of leukocytes, monocytes, macrophages, dendritic cells, mast cells, neutrophils, basophils, eosinophils, αβT cells, γδT cells, natural killer (NK) cells, natural killer T (NKT) cells, B cells, innate lymphoid cells (ILCs), cytokine-induced killer (CIK) cells, cytotoxic T lymphocytes (CTLs), lymphokine-activated killer (LAK) cells, T lymphocytes, peripheral blood mononuclear cells and hematopoietic stem cells.

10. Use of an agent in the preparation of a medicament for preventing and / or treating cancer or tumor, characterized in that: The reagent comprises: the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the blocking molecule according to claim 4, or the chimeric antigen receptor according to claim 5, or the nucleic acid molecule according to claim 6, or the vector according to claim 7, or the vector cell according to claim 8, or the immune effector cell according to claim 9; Preferably, the cancer or tumor is a cancer or tumor associated with CD7 expression; Also preferably, the cancer or tumor is a hematological malignancy; Further preferably, the hematological malignancy is a T cell-related tumor, which includes leukemia, lymphoma, and myeloma; Preferably, the use further comprises: use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the blocking molecule according to claim 4, or the chimeric antigen receptor according to claim 5, or the immune effector cell according to claim 9 in combination with other drugs; Preferably, the other drugs include diagnostic agents, prophylactic agents and / or therapeutic agents; Also preferably, the other drug is an antibody drug targeting CD20.

Citation Information

Patent Citations

  • CD7 nano antibody, coded sequence and application thereof

    CN104004095A

  • Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

    CN110268049A

  • Antagonists anti-CD7 antibodies

    CN114007699A

  • CD7-CAR-T cell as well as preparation method and application thereof

    CN114560943A

  • Anti-CD7 chimeric antigen receptor and method of use thereof

    WO2017213979A1